AFAntoni Fernandez‐Oliva

Antoni Fernandez‐Oliva

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Antoni Fernandez‐Oliva has a total of 9 co-authors. Here are the top co-authors by number of shared publications:

  • Berta Serrano

    Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain

    1 shared publication
  • Carmen Garrido-Gimenez

    Institut de Recerca Sant Pau (IR SANT PAU), Sant Quintí 77-79, 08041 Barcelona, Spain

    1 shared publication
  • Elena Carreras

    Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain

    1 shared publication
  • Erika Bonacina

    Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain

    1 shared publication
  • Helena Tur

    Maternal Fetal Medicine Unit Department of Obstetrics Hospital Universitari Valld’Hebron Universitat Autònoma de Barcelona Barcelona Spain

    1 shared publication
  • Manel Mendoza

    Maternal‐Fetal Medicine Research Group, Vall D'hebron Research Institute (VHIR), Vall D'hebron Barcelona Hospital Campus Centres de Recerca de Catalunya (CERCA) Barcelona Spain

    1 shared publication

Latest Publications

  • Soluble fms‐like tyrosine kinase to placental growth factor ratio in different stages of early‐onset fetal growth restriction and small for gestational age

    by Pablo Garcia‐Manau, Manel Mendoza, Erika Bonacina, Carmen Garrido‐Gimenez, Antoni Fernandez‐Oliva, Julia Zanini, Marina Catalan, Helena Tur, Berta Serrano, Elena Carreras

    Introduction: Increased soluble fms‐like tyrosine kinase to placental growth factor ratio (sFlt‐1/PlGF) has been demonstrated in early‐onset fetal growth restriction (FGR) and small for gestational age (SGA). sFlt‐1/PlGF cut‐offs have been described to assess preeclampsia severity; however, sFlt‐1/PlGF values present in early‐onset SGA and different FGR severity stages remain unknown. Hence, the objective of this study was to describe and compare the sFlt‐1/PlGF values and pregnancy outcomes among early‐onset SGA/FGR stages.Material and methods: This is a prospective case‐control study conducted at Vall d’Hebron University Hospital. Singleton pregnancies with estimated fetal weight .05) and pregnancy outcomes. However, all FGR stages had significantly poorer outcomes and greater sFlt‐1/PlGF values than those of SGA and controls. Furthermore, median values differed significantly among all FGR severity stages (9.76 for stage I; 284.3 for stage II, and 625.02 for stage III, P < .05) increasing with FGR severity as well as the frequency of adverse pregnancy outcomes. Additionally, a significant correlation was found between greater sFlt‐1/PlGF ratio values and gestational age at delivery, time from diagnosis to delivery, birthweight z‐scores, and time in neonatal intensive care unit (r = −.637, r = −.576, r = −.161, and r = .311, respectively).Conclusions: Values of sFlt‐1/PlGF at diagnosis permit early‐onset FGR/SGA severity classification with good correlation with Doppler ultrasound findings and the occurrence of adverse outcomes. Thus, sFlt‐1/PlGF could aid in early‐onset FGR/SGA severity classification and clinical management when Doppler assessment is not feasible.